Cargando…
Adaptive stress signaling in targeted therapy resistance in cancer
The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. While substantial progress has been achieved with the use of...
Autores principales: | Pazarentzos, Evangelos, Bivona, Trever G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546915/ https://www.ncbi.nlm.nih.gov/pubmed/25703329 http://dx.doi.org/10.1038/onc.2015.26 |
Ejemplares similares
-
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017) -
EGFR targeted therapy resistance: current status, challenges, and future outlook
por: Bivona, Trever G.
Publicado: (2020) -
Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021) -
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
por: Lin, Luping, et al.
Publicado: (2012) -
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer
por: Manabe, Tadashi, et al.
Publicado: (2022)